Master regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignancies - PubMed (original) (raw)

Review

. 2012 Jul;40(13):5819-31.

doi: 10.1093/nar/gks281. Epub 2012 Apr 5.

Affiliations

Review

Emery H Bresnick et al. Nucleic Acids Res. 2012 Jul.

Abstract

Numerous examples exist of how disrupting the actions of physiological regulators of blood cell development yields hematologic malignancies. The master regulator of hematopoietic stem/progenitor cells GATA-2 was cloned almost 20 years ago, and elegant genetic analyses demonstrated its essential function to promote hematopoiesis. While certain GATA-2 target genes are implicated in leukemogenesis, only recently have definitive insights emerged linking GATA-2 to human hematologic pathophysiologies. These pathophysiologies include myelodysplastic syndrome, acute myeloid leukemia and an immunodeficiency syndrome with complex phenotypes including leukemia. As GATA-2 has a pivotal role in the etiology of human cancer, it is instructive to consider mechanisms underlying normal GATA factor function/regulation and how dissecting such mechanisms may reveal unique opportunities for thwarting GATA-2-dependent processes in a therapeutic context. This article highlights GATA factor mechanistic principles, with a heavy emphasis on GATA-1 and GATA-2 functions in the hematopoietic system, and new links between GATA-2 dysregulation and human pathophysiologies.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

GATA factor mechanistic principles. The models depict mechanistic principles derived from studies of GATA-1 and GATA-2. While the fundamental nature of these principles is likely to be shared by other GATA factors, additional GATA factor-specific mechanistic permutations are expected. Principle 1: GATA factors occupy a very small percent of the WGATAA motifs in a genome (<1%), suggesting that crucial mechanisms exist that control the discrimination among these highly abundant motifs. However, such mechanisms are not firmly established. The model depicts the occlusion of select GATA motifs, thus creating an obligate requirement for chromatin remodeling/modification reactions to increase access of the WGATAA residues required for GATA factor binding and/or to selectively occlude the vast majority of sites. At certain sites, FOG-1 (56,57) and GATA-1 acetylation (95) enhance chromatin access. Presumably, a host of regulatory factors mediate the essential process of establishing/maintaining accessible and occluded sites. Principle 2: GATA factors activate and repress target genes via multiple mechanisms, including with or without FOG-1 (36). Presumably, this mechanistic diversity reflects the specific chromatin architecture at a genetic locus, the subnuclear environment in which the locus resides and the regulatory mileau characteristic of the specific environment. Principle 3: GATA-1 and GATA-2 commonly co-localize with Scl/TAL1, another master regulator of hematopoiesis (96), at chromatin sites. The model illustrates GATA factor and Scl/TAL1 occupancy of a composite element consisting of an E-box and a WGATAA motif, which was originally described by Wadman et al. (76). Similar to the description above, only a very small percentage of composite elements are occupied by GATA factors in cells (53,58). As co-localization does not require the E-box (72), there is much to be learned about the biochemical nature of the GATA factor and Scl/TAL1 interaction. However, the co-localization measured by ChIP often correlates with transcriptional activity (54,58,72). Principle 4: GATA switches are defined as a molecular transition in which one GATA factor replaces another from a chromatin site, which is often associated with an altered transcriptional output. The GATA switch depicted reflects that occurring at the Gata2 locus during erythropoiesis, in which GATA-1 displaces GATA-2 from chromatin, which rapidly instigates repression (87). Context-dependent GATA switches may either activate or repress transcription and, in certain cases, may sustain the original transcriptional output (36).

Figure 2.

Figure 2.

GATA-2 mutations in human hematologic disorders (143–146). Specific GATA-2 mutations in human patients are indicated, with details denoted in the legend. Each symbol represents a single patient with the particular mutation. The diagram of GATA-2 protein organization illustrates the N- and C-fingers, acetylation sites (124), the serine 401 phosphorylation site and two sumoylation consensus motifs. The diagram at the bottom illustrates the amino acid sequence composition of the C-finger and neighboring regions, with the positions of disease mutations highlighted. Stop, mutation that creates stop codon; frs, frameshift mutation; del, deletion.

Similar articles

Cited by

References

    1. Evans T, Reitman M, Felsenfeld G. An erythrocyte-specific DNA-binding factor recognizes a regulatory sequence common to all chicken globin genes. Proc. Natl Acad. Sci. USA. 1988;85:5976–5980. - PMC - PubMed
    1. Yamamoto M, Ko LJ, Leonard MW, Beug H, Orkin SH, Engel JD. Activity and tissue-specific expression of the transcription factor NF-E1 multigene family. Genes Dev. 1990;4:1650–1662. - PubMed
    1. Ho IC, Vorhees P, Marin N, Oakley BK, Tsai SF, Orkin SH, Leiden JM. Human GATA-3: a lineage-restricted transcription factor that regulates the expression of the T cell receptor alpha gene. EMBO J. 1991;10:1187–1192. - PMC - PubMed
    1. Dorfman DM, Wilson DB, Bruns GA, Orkin SH. Human transcription factor GATA-2. Evidence for regulation of preproendothelin-1 gene expression in endothelial cells. J. Biol. Chem. 1992;267:1279–1285. - PubMed
    1. Joulin V, Bories D, Eleouet JF, Labastie MC, Chretien S, Mattei MG, Romeo PH. A T-cell specific TCR delta DNA-binding protein is a member of the human GATA family. EMBO J. 1991;10:1809–1816. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources